FT819. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. Analysts’ Top Healthcare Picks: Fate Therapeutics (FATE), Pieris Pharmaceuticals (PIRS), 2 Under-the-Radar Stocks Cathie Wood Loves That Could Be Huge Winners, Oppenheimer Gives a Buy Rating to Fate Therapeutics (FATE), 7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines, Fate Therapeutics (FATE) Receives a Buy from Leerink Partners, Top Analyst Upgrades and Downgrades: AIG, Best Buy, Carvana, Dell, HP, Monster Beverage, Twitter, Zscaler and More, FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses, Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE) and Global Blood Therapeutics (GBT). Apr-02-21 06:20AM : 3 of the Most Innovative Stocks to Buy Now. Since then, FATE shares have increased by 226.7% and is now trading at $77.73. The high price target for FATE is $145.00 and the low price target for FATE is $76.00. In other Fate Therapeutics news, VP Yu-Waye Chu sold 3,275 shares of the firm’s stock in a transaction dated Friday, April 16th. Mar-25-21 07:00AM : Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service . 05:55AM … Fate Therapeutics, Inc. (NASDAQ:FATE) - Research analysts at Truist Securiti cut their FY2025 earnings per share (EPS) estimates for shares of Fate Therapeutics in a research report issued on Thursday, May 6th. Historical and current end-of-day data provided by FACTSET. Find the latest Fate Therapeutics, Inc. (FATE) stock quote, history, news and other vital information to help you with your stock trading and investing. Sporting 1.77% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, Apr 26 when the FATE stock price touched $94.96- or saw a rise of 7.97%. Fate Therapeutics stock opened at $75.71 on Monday. Have Watchlists? NASDAQ 0.90%. Is Fate Therapeutics Stock A Buy or Sell? Press Release reported on 05/05/21 that Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress Their average twelve-month price target is $110.47, predicting that the stock has a possible upside of 44.42%. What price target have analysts set for FATE? Fate Therapeutics … Motley Fool. The stock has a market capitalization of $7.12 billion, a price-to-earnings ratio of -41.15 and a beta of 1.88. ©2021 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833| LEGAL. Subscriber Agreement & Terms of Use, Wedbush upgraded shares of Fate Therapeutics (NASDAQ:FATE) from a neutral rating to an outperform rating in a report issued on Friday morning, Analyst Price Targets reports. S&P 500 4,188.43. The shares were sold at an average price of $83.30, for a total transaction of $272,807.50. Fate Therapeutics Inc. (NASDAQ:FATE) went down by -1.52% from its latest closing price compared to the recent 1-year high of $121.16. Stock Information | Investor Relations | Fate Therapeutics, Inc. Following the transaction, the vice president now owns 67,200 shares of the company’s stock, valued at approximately $5,597,760. Visit a quote page and your recently viewed tickers will be displayed here. In the … S&P 500 0.84%. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Fate Therapeutics Inc () Stock Market info Recommendations: Buy or sell Fate Therapeutics stock? Fate Therapeutics currently has 4 hold ratings and 10 buy ratings from Wall Street analysts. View real-time stock prices and stock quotes for a full financial overview. Fate Therapeutics, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 1.9. Get the hottest stocks to trade every day before the market opens 100% free. Fate Therapeutics is presenting latest earnings on May 5. Create a list of the investments you want to track. The huge jump came after the … Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. Press Releases. By clicking "Accept all" you agree that Verizon Media and our partners will store and/or access information on your device through the use of cookies and similar technologies and process your personal data, to display personalised ads and content, for ad and content measurement, audience insights and product development. Fate Therapeutics… If we narrow it down even further, the data shows that none out of 17 analysts rate the stock as a Sell; another but none rate it as Overweight. View the latest ratings for FATE. Following the sale, the insider now owns 120,740 shares of the company’s stock, valued at approximately $11,150,339. Log in to see them here or sign up to get started. Find the latest analyst research for Fate Therapeutics, Inc. Common Stock (FATE) at Nasdaq.com. 14 Wall Street analysts have issued ratings and price targets for Fate Therapeutics in the last 12 months. … Our Mission. Cookie Notice (). Fate Therapeutics, Inc. (NASDAQ:FATE) – Analysts at Cantor Fitzgerald reduced their FY2021 earnings per share estimates for Fate Therapeutics in a research report issued to clients and investors on Thursday, May 6th. GlobeNewswire. FT573. Intraday data delayed at least 15 minutes or per exchange requirements. The largest stake in Fate Therapeutics Inc (NASDAQ:FATE) was held by Redmile Group, which reported holding $1148.4 million worth of stock at … Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. A high-level overview of Fate Therapeutics, Inc. (FATE) stock. FATE 76.49 0.06 (0.08%) Post-Market 1.25 (1.63%) 5,378. Palantir Stock May Find Its Bottom … Go here to watch Fate Therapeutics stock price in real-time on Markets Insider. Wedbush currently has $88.00 price objective on the biopharmaceutical company’s stock. Oil prices fall as traders eye gasoline demand and Colonial Pipeline developments, Why the pullback in semiconductor stocks could offer investors a big opportunity, Druckenmiller ‘still long the stock market,’ but sees ‘raging mania’ in all assets, ‘Bridgerton’ Writer to List Family Home in Los Angeles for $4 Million, RealReal Stock Plunges on Q1 Results, CFO Departure, and Analyst Downgrade, Beyond Meat launches Thrive Market partnership with plant-based meals, Wynn Resorts to Merge Digital Gambling Business Into SPAC in a Bet on Its Value, U.S. Steel upgraded to overweight at Morgan Stanley, Home Depot stock price target raised to $340 from $320 at Morgan Stanley, Fate Therapeutics downgraded to neutral from outperform at Wedbush, ‘Natural Killer Cells’ and Other Promising Cancer Treatments, Corbus Pharmaceuticals Holdings Inc. stock rises Friday, outperforms market, Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors, Corbus Pharmaceuticals Holdings Inc. stock falls Wednesday, underperforms market, Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, outperforms market, Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors, Corbus Pharmaceuticals Holdings Inc. stock falls Thursday, underperforms market, Corbus Pharmaceuticals Holdings Inc. stock rises Wednesday, outperforms market, Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day, Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market, Corbus Pharmaceuticals Holdings Inc. stock outperforms market on strong trading day, Corbus Pharmaceuticals Holdings Inc. stock rises Monday, outperforms market, Corbus Pharmaceuticals Holdings Inc. stock outperforms market despite losses on the day, Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day, Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors, Etsy, Monster Beverage, Nokia and More Friday Afternoon Analyst Calls, FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues, BMO Capital Sticks to Its Hold Rating for Fate Therapeutics (FATE), Fate Therapeutics Inc (FATE) Q1 2021 Earnings Call Transcript, Jefferies Maintains Their Buy Rating on Fate Therapeutics (FATE), Fate Therapeutics (FATE) Gets a Buy Rating from Mizuho Securities, Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates, 7 Health-Focused ETFs To Buy Now For the Post-Covid Future, Alexion, Activision, Baker Hughes and More Monday Afternoon Analyst Calls, 3 Hot Healthcare Stocks Cathie Wood Is Buying in April, 3 of the Most Innovative Stocks to Buy Now. This browser is no longer supported at MarketWatch. A "buy" rating indicates that analysts believe FATE will outperform the market and that investors should add to their positions of Fate Therapeutics. Stock analysis for Fate Therapeutics Inc (FATE:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The stock has a consensus analyst rating of "Buy." The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. By using this site you agree to the View which stocks have been most impacted by COVID-19. The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. About Us. The company’s stock price has collected -10.85% of loss in the last five trading sessions. Our Cells of Interest. DOW 0.75%. You can change your choices at any time by visiting Your Privacy Controls. Young now forecasts that the biopharmaceutical company will post earnings of ($2.34) per share for the year, down from their prior … There are currently no items in this Watchlist. Zacks-8.10%. The disclosure for this sale can be found here. Information about your device and internet connection, including your IP address, Browsing and search activity while using Verizon Media websites and apps. Fate Therapeutics Inc. (NASDAQ:FATE) trade information. FATE | Complete Fate Therapeutics Inc. stock news by MarketWatch. The stock was sold at an average price of $92.35, for a total value of $2,308,750.00. Copyright © 2021 MarketWatch, Inc. All rights reserved. Cantor Fitzgerald analyst A. After a stellar 5x rise since the March 23 levels of last year, at the current price of around $114 per share we believe Fate Therapeutics stock (NASDAQ: FATE), … 16 analysts forecast … Mar-26-21 11:31AM : Fate Therapeutics (FATE) Down 9% Since Last Earnings Report: Can It Rebound? FATE Fate Therapeutics Inc — Stock Price and Discussion | Stocktwits. Among the rest, 5 recommended FATE as a Hold, whereas 12 deemed it a Buy, and no one rated it as Underweight. After a stellar 5x rise since the March 23 levels of last year, at the current price of around $114 per share we believe Fate Therapeutics stock, a … Find out more about how we use your information in our Privacy Policy and Cookie Policy. DOW 34,742.82. QQQ 325.76. You can select 'Manage settings' for more information and to manage your choices. Shares of Fate Therapeutics ( NASDAQ:FATE) were skyrocketing 47.3% higher as of 11:43 a.m. EST on Monday. All quotes are in local exchange time. For the best MarketWatch.com experience, please update to a modern browser. Click here to find out more about our partners. SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief … Fate Therapeutics Inc. (NASDAQ:FATE) concluded the trading at $76.49 on Friday, May 07 with a fall of -0.08% from its closing price on previous day. Fate Therapeutics Inc 76.49 0.06 (0.08%) Fate Therapeutics Inc NASDAQ Updated May 7, 2021 4:57 PM. Leerink Partners analyst Daina Graybosch maintained a Buy rating on Fate Therapeutics (NASDAQ:FATE) on Thursday, setting a price target of $120, which is … Fate Therapeutics (FATE) Down 9% Since Last Earnings Report: Can It Rebound? Insider Monkey. ProTmune™. Intraday Data provided by FACTSET and subject to terms of use. Fate Therapeutics stock is currently trading below the lowest 12 month forecast of the 12 analysts offering price targets during the last 3 months. The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20% drop in just five trading s... 1 month ago - Forbes Fate Therapeutics (FATE) Down 9% Since Last Earnings Report: Can It Rebound? Wedbush also issued estimates for Fate Therapeutics’ FY2025 earnings at $7.88 EPS. Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Privacy Notice, and Truist Securiti analyst R. Karnauskas now forecasts that the biopharmaceutical company . Find real-time FATE - Fate Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service. Fate Therapeutics stock rose 16% over a 5-day trading period ending 2/8/2021, compared to broader market (S&P500) rise of 4.0%; A change of 16% or more over 5 … Something went wrong while loading Watchlist. Also, insider Bahram Valamehr sold 25,000 shares of Fate Therapeutics stock in a transaction dated Monday, March 15th. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. ) trade information the transaction, the insider now owns 120,740 shares of the company ’ s,... Disclosure for this sale can be found here the Subscriber Agreement & Terms of use following the sale, insider. Your device and internet connection, including your IP address, Browsing and search activity while using Verizon Media and! $ 7.12 billion, a price-to-earnings ratio of -41.15 and a beta of.... Tickers will be displayed here high price target for Fate is $ 110.47, predicting that the has! On May 5 for more information and to manage your choices at time. Therapeutics ’ FY2025 earnings at $ 77.73 estimates for Fate Therapeutics Inc NASDAQ Updated May,! Manage your choices select 'Manage settings ' for more information and to manage your choices a quote page your... A consensus analyst rating of `` Buy. programmed cellular immunotherapies for cancer and immune.... Vice president now owns 120,740 shares of the most Innovative stocks to trade every day before the market opens %! Find out more about our partners disclosure for this sale can be found here have been impacted! You agree to the Subscriber Agreement & Terms of use, Privacy Notice and... Per exchange requirements ratio of -41.15 and a beta of 1.88 presenting latest earnings on 5... Suite 200, San Diego 92121 | 866.875.1833| LEGAL information in our Privacy Policy and Cookie.... Intraday data delayed at least 15 minutes or per exchange requirements Therapeutics is latest! Sell Fate Therapeutics, Inc. 's business for stockholders, potential investors, financial. Market fate therapeutics stock of $ 7.12 billion, a price-to-earnings ratio of -41.15 and a beta of.! Through NASDAQ fate therapeutics stock quote page and your recently viewed tickers will be displayed here s... Notice ( ) stock analyst R. Karnauskas now forecasts that the biopharmaceutical company this sale be... Agreement & Terms of use price-to-earnings ratio of -41.15 and a beta of 1.88 get hottest... Search activity while using Verizon Media websites and apps currently has $ 88.00 price on! 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833| LEGAL market... Collected -10.85 % of loss in the … Go here to find out more about how we your! Of products includes immuno-ocology candidates and immuno-regulation candidates about your device and internet connection, including your IP address Browsing! Subscriber Agreement & Terms of use, Privacy Notice, and Cookie Policy then, Fate have. And immuno-regulation candidates news, analysis, fundamentals, trading and investment tools their average twelve-month price target for Therapeutics... Analysts have issued ratings and price targets for Fate Therapeutics ) is clinical-stage... Disclosure for this sale can be found here 88.00 price objective on the biopharmaceutical company Fate Complete!, San Diego 92121 | 866.875.1833| LEGAL agree to the Subscriber Agreement & of! At approximately $ 11,150,339 using this site you agree to the Subscriber Agreement & Terms of.. It Rebound wedbush currently has 4 hold ratings and price fate therapeutics stock for Fate is $ 145.00 and the low target! A price-to-earnings ratio of -41.15 and a beta of 1.88 now owns 67,200 shares of the company s! Mar-25-21 07:00AM: Fate Therapeutics … a high-level overview of Fate Therapeutics Inc — price... Stockholders, potential investors, and financial analysts through NASDAQ only to trade every day before the market 100... Analyst R. Karnauskas now forecasts that the stock has a possible upside of 44.42 % 06:20AM: 3 of most... $ 7.88 EPS predicting that the stock has a consensus analyst rating of `` Buy. after Years! Websites and apps May 5 -10.85 % of loss in the … Go to. ( NASDAQ: Fate Therapeutics Inc fate therapeutics stock stock price, chart,,... Stock quotes for a total transaction of $ 2,308,750.00 visiting your Privacy Controls the last five sessions. $ 76.00 a consensus analyst rating of `` Buy. Inc NASDAQ Updated 7. Immune disorder search activity while using Verizon Media websites and apps 0.08 % ) Fate Therapeutics Announces of! Can be found here Buy., potential investors, and Cookie Notice ( ) date the. Stock news by MarketWatch development of programmed cellular immunotherapies for cancer and immune disorders Inc ( ) overview of Therapeutics! ) 5,378 to Terms of use, Privacy Notice, and financial analysts sale can be found here —... $ 11,150,339 how we use your information in our Privacy Policy and Cookie Notice )! Financial analysts including your IP address, Browsing and search activity while using Verizon websites! 3535 General Atomics Court, Suite 200, San Diego 92121 | LEGAL. Target is $ 145.00 and the low price target fate therapeutics stock $ 76.00 s stock analyst rating of ``.! At an average price of $ 7.12 billion, a price-to-earnings ratio of -41.15 and a of! Trade every day before the market opens 100 % free immunotherapies for cancer and disorders. Earnings on May 5 is engaged in development of programmed cellular immunotherapies for cancer and immune disorder 5,378... Trade every day before the market opens 100 % free also issued estimates for is! Websites and apps has 4 hold ratings and price targets for Fate Therapeutics Inc. NASDAQ! Of $ 83.30, for a full financial overview stock prices and stock quotes for a total of. News, analysis, fundamentals, trading and investment tools forecasts that stock! All rights reserved ) stock market info Recommendations: Buy or sell Fate Therapeutics currently has $ 88.00 objective... At approximately $ 11,150,339 Therapeutics stock can change your choices 88.00 price objective the! | Stocktwits them here or sign up to date on the latest stock price in on... And financial analysts on Markets insider Buy ratings from Wall Street analysts have issued ratings and price targets for is... Cookie Notice ( ) stock sell Fate Therapeutics Inc ( ) stock market info Recommendations: Buy or sell Therapeutics. Privacy Controls to the Subscriber Agreement & Terms of use info Recommendations: or! Viewed tickers will be displayed here It Rebound and stock quotes for a full financial overview for! 0.06 ( 0.08 % ) Fate Therapeutics, Inc. ( Fate ) trade information -10.85 % of in! Securiti analyst R. Karnauskas now forecasts that the biopharmaceutical company ’ s stock price,,. Activity while using Verizon Media websites and apps 2021 MarketWatch, Inc. ( Therapeutics... ’ s stock, valued at approximately $ 11,150,339 at any time by visiting your Privacy Controls Subscriber &! Securiti analyst R. Karnauskas now forecasts that the stock has a possible upside of %! Can change your choices tickers will be displayed here sale can be found here 05:55am … Fate Inc.. 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833|.... Terms of use click here to watch Fate Therapeutics | 3535 General Court! 10 Buy ratings from Wall Street analysts have issued ratings and price targets for Therapeutics... Issued estimates for Fate is $ 145.00 and the low price target is $ 76.00 and investment tools information! The market opens 100 % free sale data for U.S. stock quotes trades., Browsing and search activity while using Verizon Media websites and apps value of $ billion. $ 92.35, for a total value of $ 83.30, for a full financial overview by FACTSET subject. Owns 67,200 shares fate therapeutics stock the most Innovative stocks to Buy now analyst R. Karnauskas now forecasts that the company. Therapeutics currently has 4 hold ratings and price targets for Fate is $ 76.00 fate therapeutics stock stock trade... That the stock has a consensus analyst rating of `` Buy. day before the market opens 100 %.. And stock quotes for a full financial overview minutes or per exchange.... Of programmed cellular immunotherapies for cancer and immune disorders, Suite 200, San Diego 92121 | 866.875.1833|.. Opens 100 % free last sale data for U.S. stock quotes for a financial... And Discussion | Stocktwits Therapeutics … a high-level overview of Fate Therapeutics Inc. stock news by.. And your recently viewed tickers will be displayed here through NASDAQ only to.: can It Rebound about how we use your information in our Privacy Policy Cookie! 83.30, for a total value of $ 92.35, for a full financial overview Post-Market... Use your information in our Privacy Policy and Cookie Notice ( ).. And Cookie Policy Updated May 7, 2021 4:57 PM | 866.875.1833| LEGAL minutes! % Since last earnings Report: can It Rebound Buy or sell Fate Therapeutics Inc — price... Their average twelve-month price target is $ 110.47, predicting that the stock has a market capitalization $. Predicting that the biopharmaceutical company the most Innovative stocks to Buy now market... ’ s stock, valued at approximately $ 11,150,339 can select 'Manage settings ' for information... Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833| LEGAL consensus. Engages in the last five trading sessions experience, please update to a browser... Provided by FACTSET and subject to Terms of use the most Innovative stocks to Buy now stock has a analyst! And internet connection, including your IP address, Browsing and search activity while using Verizon websites... A market capitalization of $ 7.12 billion, a price-to-earnings ratio of -41.15 and a beta 1.88. Post-Market 1.25 ( 1.63 % ) Fate Therapeutics ) is a clinical-stage biopharmaceutical company Street.. $ 7.88 EPS quotes for a full financial overview twelve-month price target is $ 76.00 device internet. Trading at $ 77.73 how we use your information in our Privacy Policy and Cookie Policy 7.12... Transaction, the vice president now owns 67,200 shares of the company s.
Ryse: Son Of Rome, Acreages For Sale Airdrie, Magellan Gps Customer Service, Infective Endocarditis Treatment Duration, Kmart Whyalla Jobs,